Note: Descriptions are shown in the official language in which they were submitted.
CA 02373859 2002-11-06
1
DESCRIPTION
BLOOD CARBONYL COMPOUND-TRAPPING AGENT
Technical Field
The present invention relates to the removal of blood carbonyl
compounds, specifically, to the removal of blood carbonyl compounds
using a carbonyl compound-trapping agent.
Background Art
Hemodialysis is a typical therapy used for treating patients
with chronic renal failure, wherein blood waste products and toxic
substances are removed by contacting blood with a dialysate via a
semipermeable membrane. However, the disease state of renal
failure cannot completely be inhibited by dialysis. Such a disease
state includes increase of advanced glycation end products (AGEs)
and carbonyl intermediate (precursors of AGE) levels in renal
failure patients. AGEs have been reported to modify protein
structure and function and to be involved in the onset of
complications of dialysis, such as dialysis amyloidosis and
arteriosclerosis (Makita, Z. et al.. , N. Engl. J. Med., 325: 836-842,
1991; Miyata, T. et al., J. Clin. Invest., 92: 1243-1252, 1993;
Miyata, T. et al., J. Clin. Invest., 93: 521-528, 1994; Miyata, T.
et al., Proc. Natl. Acad. Sci. USA, 9:3: 2353-2358, 1996; Horie, K.
et al., J. Clin. Invest., 100: 2995-3004, 1997; Miyata, T. et al.,
FEBS letters, 445: 202-206, 1999). Recently, it was revealed that
the accumulation of carbonyl intermediates such as glyoxal,
methylglyoxal, 3-deoxy glucosone and arabinose (so-called,
carbonyl stress) (Odani et al., Biochem. Biophys. Res. Commun., 256:
89-93, 1999; Niwa et al., Nephron, 69: 438-443, 1995; Miyata et al.,
Kidney Int., 55: 389-399, 1999; Miyata et al ., J. Am. Soc. Nephrol.,
9: 2349-2356, 1998) in blood plasma results in an increased AGE level
in renal failure (Miyata, T. et al., J. Am. Soc. Nephrol., 9:
2349-2356, 1998; Miyata, T. et al., Kidney Int., 55: 389-399, 1999) .
A va'riety of carbonyl intermediates (AGE precursors) derive mainly
from carbohydrates and lipids (Miyata, T. et al., Kidriey Int. , 55:
389-399, 1999; Miyata, T. et al., Kidney Int., 54; 1290-1295, 1998;
CA 02373859 2002-11-06
2
Miyata, T. et al. , Kidney Int. , 51: 1170-1181, 1997 ). Conventional
hemodialysis cannot effectively remedy these increased levels of
AGE and carbonyl intermediates, namely "carbonyl stress", in renal
failure patients.
Disclosure of the Invention
An objective of the present invention is to provide a carbonyl
compound-trapping agent for removing blood carbonyl compounds.
Another objective of the present invention is to provide a method
and agent for improving carbonyl stress state in a living body. The
present invention enables to prevent the damage caused by carbonyl
compounds in hemodialysis patients who are particularly prone to
fall into a carbonyl stress state. The objective of the present
invention is to reduce the damage by carbonyl compounds as much as
possible in hemodialysis patients.
First, the present inventors studied how the hemodialysis
membrane used for hemodialysis influenced the quantity of carbonyl
compounds in patients' blood. The content of blood pentosidine,
a marker for the accumulation of carbonyi intermediate products (i.e.
carbonyl stress), was compared by quantification with
high-performance liquid chromatography (HPLC) for each type of
dialysis membrane used by dialysis patients. The result showed that
free pentosidine was markedly removed by dialysis through any
dialysis membrane, while protein-bound pentosidine, which occupies
the major portion of pentosidine in the body could not be effectively
removed by dialysis.
Comparing the type of dialysis membrane indicated no
difference in the value of protein-bound and free pentosidine with
low-flux cellulosic, high-flux polymethyl methacrylate (PMMA) and
AN69, but the value was lower with high-flux polysulfone (PS)
(p<0.01). There were no differences of the value depending on
whether the patient was Japanese or Belgian, or on the manufacturer
of the PS membrane. Switching the dialysis membrane used by three
patients from AN69 to PS decreased the protein-bound pentosidine
level, and then, return to AN69 increased the level back to the
original. These results revealed that polysulfone membrane is
effective as a dialysis membrane for suppressing the aeneration of
CA 02373859 2002-11-06
:S
carbonyl compounds.
Then, the present inventors conceived the utilization of a
carbonyl compound-trapping agent for the effective removal of blood
carbonyl compounds. Blood plasma prepared from the blood of
dialysis patients was incubated with carriers on which a carbonyl
compound-trapping agent had been immobilized, and blood carbonyl
compounds were quantified. The result showed that the incubation
with carriers on which a carbonyl compound-trapping agent had been
immobilized significantly reduced the quantities of blood carbonyl
compounds.
Based on these findings, the present inventors focused on
carbonyl compounds accumulated in blood and thought that the removal
of carbonyl compounds accumulated in blood was required for
improving carbonyl stress, mainly protein modificatior_, in dia:Lysis
patients. Then, the inventors found that the use of a compound
having the function of eliminating or reducing the protein
modification activity of carbonyl compounds by chemically reacting
with or adsorbing carbonyl compounds was effective to achieve the
objective, and thus completed the present invention. In the present
invention, a carrier, on which a compound having such a function
has been immobilized, or the compound itself, is called a"carbonyl
compound-trapping agent".
Namely, the present invention relates to a carbonyl
compound-trapping agent for removing blocd carbonyl compounds, as
well as a method and agent for improving carbonyl stress state in
a living body as described below:
(1) a carbonyl compound-trapping agent that removes a blood carbonyl
compound;
(2) the carbonyl compound-trapping agent according to (1), wherein
said agent is used in tiemodialysis;
(3) the carbonyl compound-trapping agent according to (1), wherein
said agent is immobilized on a blood-insoluble carrier;
(4) the carbonyl compound-trapping agent according to (3), wherein
said carrier is a dialysis membrane;
(5) the carbonyl compound-trapping agent according to (4), wherein
said dialysis membrane is a polysulfone membrane;
(6) the carbonyl compound-trapping agent according to (1), wherein
CA 02373859 2002-11-06
4
said carbonyl compound-trapping agent is a Maillard reaction
inhibitor;
(7) the carbonyl compound-trapping agent according to (6), wherein
said Maillard reaction inhibitor comprises at least one compound
selected from the group consisting of aminoguanidine, pyridoxamine,
hydrazine, SH group-containing compound, and derivatives thereof;
(8) the carbonyl compound-trapping agent according to (1), wherein
said agent comprises a compound that is insoluble iri blood;
(9) the carbonyl compound-trapping agent according to (8), wherein
said compound that is insoluble in blood comprises at least one
compound selected from the group consisting of an ion exchange resin,
activated carbon, silica gel, alumina, and calcium carbonate;
(10) an agent for improving the carbonyl stress state in a living
body, wherein said agent comprises a carbonyl compound-trapping
agent as an active ingredient;
(11) an agent for improving the carbonyl stress state in blood,
wherein said agent comprises a carbonyl compound-trapping agent as
an active ingredient;
(12) the agent for improving the carbonyl stress state according
to (11) , wherein said agent is immobilized within the blood circuit;
(13) the agent for improving the carbonyl stress state according
to (11) , wherein the carbonyl compound-trapping agent is a Maillard
reaction inhibitor;
(14) the agent for improving the carbonyl stress state according
to (13), wherein said Maillard reaction inhibitor comprises at least
one compound selected from the group consisting of aminoguanidine,
pyridoxamine, hydrazine, SH group-containing compound, and
derivatives thereof;
(15) a method for improving carbonyl stress state, wherein said
method comprises the step of contacting, within the blood circuit,
a patient's blood with a carbonyl compound-trapping agent;
(16) the method according to (15), wherein said method comprises
the step of immobilizing said carbonyl compound-trapping agent on
a blood-insoluble carrier.
The present invention also relates to the use cf a carbonyl
compound-trapping agent for removing blood carbonyl compounds.
Further, the present invention relates to the use of a carbonyl
CA 02373859 2002-11-06
~J
compound-trapping agent for manufacturing an agent for improving
blood carbonyl stress.
In the present invention, carbonyl compounds to be trapped
include, for example, the following compounds that accumulate in
the blood of renal failure patients together with oxidative stress.
Carbonyl compounds derived from carbohydrates:
=arabinose
=glyoxal
=methylglyoxal
=3-deoxyglucosone
Carbonyl compound derived from ascorbic acid:
=dehydroascorbic acid
Carbonyl compound derived from lipid:
=hydroxynonenal
=malondialdehyde
=acrolein
A preferred carbonyl compound-trapping agent in the present
invention is one capable of completely inhibiting or reducing the
protein-modification activity of all. these carbonyl compounds
through a chemical reaction or adsorption. However, the carbonyl
compound-trapping agent of the presei:t invention also includes an
agent effective for the major carbonyl compounds among these.
Carbonyl compound-trapping agents that can be used iri the present
invention include, for example, the following compounds:
= aminoguanidine (Foote, E. F. etal., Am. J. KidneyDis., 25: 420-425
(1995))
= 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide
(OPB-9195; S. Nakamura, 1997, Diabetes 46:895-899)
Further, the carbonyl compound-trapping agent includes, for
example, the following compounds or derivatives thereof tha-_ are
capable of functioning as carbonyl compound-trapping agents.
"Derivatives" indicate compounds having an atomic or molecular
substitution(s) at any position ascompared with the parent compound.
By linking to carriers to facilitate separation from blood, these
compounds can be used as carbonyl compound-trapping agents in the
present invention. Alternatively, if the compound itself is
insoluble in blood, it can be used as the carboriyl compound-trapping
CA 02373859 2002-11-06
6
agent of this invention without being immobilized on carriers.
(1) guanidine derivatives such as methylguanidine (JP-A Sho
62-142114; JP-A Sho 62-249908; JP-A Hei 1-56614; JP-A Hei 1-83059;
JP-A Hei 2-156; JP-A Hei 2-765; JP-A Hei 2-42053; JP-A Hei 6-9380;
Published Japanese Translation of International Publication
5-505189), etc.
(2) hydrazine derivatives such as sulfonylhydrazine, etc.
(3) five-membered heterocyclic compounds having two nitrogen
atoms, such as pyrazolone (JP-A Hei 6-287179), pyrazoline (JP-A
HeilO-167965), pyrazole (JP-A Hei 6-192089; JP-A Hei6-298737; JP-A
Hei 6-298738), imidazolidine (JP-A Hei 5-201993; JP-AIIei 6-135968;
JP-A Hei7-133264; JP-A Hei 10-182460), hydantoin (JP-A Hei
6-135968), etc.
(4) five-membered heterocyclic compounds having three
nitrogen atoms, such as triazole (JP-A Hei 6-192089), etc.
(5) five-membered heterocyclic compounds having a nitrogen
atom and a sulfur atom, such as thiazoline (JP-A Hei 10-167965),
thiazole (JP-A Hei 4-9375; JP-A Hei 9-59258), thiazolidine (JP-A
Hei 5-201993; JP-A Hei 3-261772; JP-A Hei 7-133264; JP-A Hei
8-157473), etc.
(6) five-membered heterocyclic compounds having a nitrogen
atom and an oxygen atom, such as oxazole (JP-A Hei 9-59258), etc.
(7) nitrogen-containing six-membered heterocyclic compounds
such as pyridine (JP-A Hei 10-158244; JP-A Hei 10-175954),and
pyrimidine (Published Japanese Translation of International
Publication 7-500811), etc.
(8) nitrogen-containing condensed heterocyclic compounds such
as indazole (JP-A Hei 6-287180), benzimidazole (JP-A Hei 6-305964),
quinoline (JP-A Hei 3-161441), etc.
(9) sulfur- and nitrogen-containing condensed heterocyclic
compounds such as benzothiazole (JP-A Hei 6-305964), etc.
(10) sulfur-containing condensed heterocyclic compound such
as benzothiophene (JP-A Hei 7-196498), etc.
(11) oxygen-containing condensed heterocyclic compounds such
as benzopyran (JP-A Hei 3-204874; JP-A Hei 4-308586;, etc.
(12) nitrogenous compounds such as carbazoyl (JP--A Hei 2-156;
JP-A Hei 2-753), carbazic acid (JP-A Hei 2-167264), hydrazine (JP-A
CA 02373859 2002-11-06
Y
Hei 3-148220), etc.
(13) quinones such as benzoquinone (JP-A Hei 9-315960), and
hydroquinone (JP-A Hei 5-9114), etc.
(14) aliphatic dicarboxylic acids (JP-A Hei 1-56614; JP-A Hei
5-310565)
(15) silicone containing compounds (JP-A Sho 62-249709)
(16) organic germanium compounds (JP-A Hei 2-62885; JP-A Hei
5-255130; JP-A Hei 7-247296; JP-A Hei 8-59485)
(17) flavonoids (JP-A Hei 3-240725; JP-A Hei 7-206838; JP-A
Hei 9-241165; WO 94/04520)
(18) alkylamines (JP-A Hei 6-206818; JP-A Hei 9-59233; JP-A
Hei 9-40626; JP-A Hei 9-124471)
(19) amino acids (Published Japanese Translation of
International Publication 4-502611; Published Japanese Translation
of International Publication 7-503713)
(20) aromatic compounds such as ascochloriri (JP-A Hei
6-305959), benzoic acid (WO 91/11997), pyrrolo-naphthyrid.inium
(JP-A Hei 10-158265), etc.
(21) polypeptides (Published Japanese Translation of
International Publication 7-500580)
(22) vitamins such as pyridoxamine (WO 97/09981), etc.
(23) SH group-containing compounds such as glutathione,
cysteine, N-acetylcysteine, etc.
(24) SH group-containing proteins such as reduced albumin, etc.
(25) tetracyclines (JP-A Hei 6-256280)
(26) chitosans (JP-A Hei 9-221427)
(27) tannins (JP-A Hei 9-40519)
(28) quaternary ammonium ion-containing compourids
(29) biguanides such as metformin, phenformin and buformin
(30) polymer compounds such as ion exchange resins
(31) inorganic compounds such as activated carbon, silica gel,
alumina and calcium carbonate.
Most of the above compounds are generally known.as Maillard
reaction inhibitors. Maillard reaction -neans a non--enzymatic
glycation reaction between a reducing sugar such as glucose, and
an amino acid or protein. Focusing on a phenomenon of brown
coloration in a mixture consisting of amino acid and reducing sugar
CA 02373859 2002-11-06
8
upon heating, Maillard reported this reaction in 1912 (Maillard,
L. C., Compt. Rend. Soc. Biol., 72: 599 (1912). Maillard reaction
is involved in brown coloration of food, generation of aromatic
components and taste, and protein denaturation during heating or
storage. Therefore, this reaction has been mainly studied in the
field of food chemistry.
In 1968, glycated hemoglobin (HbAlc), a micro fraction of
hemoglobin, was identified in vivo, which was found to increase in
patients with diabetes (Rahbar. S., Clin. Chim. Acta, 22: 296 (1968)).
These findings helped launch a wave of interest in th= significance
of the in vivo Maillard reaction and the participation of the reaction
in the onset of adult diseases, such as diabetic complications and
arteriosclerosis as well as the progress of aging. Aqentsinhibiting
the in vivo Maillard reaction were explored intensively, resulting
in the discovery of the above-mentioned compounds as agents inhibiting
the Maillard reaction.
However, it was not known that such Maillard reaction inhibitors
are capable of improving the carbonyl-stress state in
peritoneal-dialysis patients by eliminating carbonyl compounds from
the blood.
There is no particular limitation on the type of carrier to
be used for the immobilization of the carbonyl compound-trapping
agent of the present invention, as long as it is insoluble in blood
and harmless to the human body, and is also safe and stabile as a
material directly contacting blood. Specifically, such carriers
include, for example, synthetic or naturally occurring organic
polymer compounds, inorganic materials such as glass beads, silica
gel, alumina, and activated carbon, and those of which surfaces are
coated with polysaccharide or synthetic polymer.
A carrier comprising a polymer compounds is exemplified by a
polymethyl methacrylate, polyacryloiiitrile, polysulfone, vinyl,
polyolefin, fluorine, polyester, polyamide, polyimide,
polyurethane, polyacryl, polystyrene, polyketone, silicon,
cellulose, chitosan; specifically, polysaccharides such as agarose,
cellulose, chitin, chitosan, sepharose, dextran, etc. and
derivatives thereof, and polyester, polyvinyl chloride,
polystyrene, polysufone, polyethersulfone, polypropylene,
CA 02373859 2002-11-06
9
polyvinyl alcohol, polyarylether sulfone, polyacrylic ester,
polymethacrylic ester, polycarbonate, acetylated cellulose,
polyacrylonitrile, polyethylene terephthalate, polyamide,
silicone resin, fluororesin, polyurethane, polyetherurethane, and
polyacrylamide and derivatives thereof. These polymer materials
can be used alone or in a combination of two or more types of polymers.
In the latter case, the carbonyl compound-trapping agent is
immobilized on at least one of the polymers. The immobilized
carbonyl compound-trapping agent is used alone or in la: combination
of two or more types of compounds. Also, it is possible to add an
appropriate modifier to these polymer materials or, subject them
to denaturation treatment such as closs-linking by irradiation or
peroxide.
There is no restriction on the shape of carrier. For example,
the carrier can be membrane-like, fiber-like, granular-shaped,
hollow fiber-like, non-woven fabric-like, porous, or
honeycomb-shaped. The carrier's area of contact with the
peritoneal dialysate can be controlled by varying the thickness,
surface area, diameter, length, shape, and/or size of the carrier.
The carbonyl compound-trapping agent can be immobilized on
the above-mentioned carrier by using known methods, such as physical
adsorption, specific biochemical binding reaction, ion binding,
covalent bonding, grafting, etc. If necessary, a spacer can be
inserted between the carrier and the carbonyl compound-crapping
agent. When the carbonyl compound-trapping agent is toxic, the
amount released becomes a vital issue. Thus, it is preferred that
the carbonyl. compound-trapping agent is immobilized on the carrier
by a covalent bond so as to minimize the amount released. Functional
groups on the carrier are utilized for covalently bonding the
carbonyl compound-trapping agent thereto. The functional group
used is, for example, hydroxyl group, amino group, aldehyde group,
carboxyl group, thiol group, silanol group, amide group, epoxy
group, succinylimino group, etc.; however, the functional group is
not limited to these groups. As examples of covalent bonds, ester
bond, ether bond, amino bond, amid bond, sulfide bond, imino bond,
disulfide bond, or the like can be given.
A coinmercially available product, for example polystyrene
CA 02373859 2002-11-06
carrier having sulfonylhydrazine groups (PS-TsNHNH2, ARGONAUT
TECHNOLOGIES C0. ), can be used as a carrier for immobilizing carbonyl
compound-trapping agent.
The carrier with the immobilized carbonyl compound-trapping
agent of the present invention can be sterilized by ari appropriate
sterilization method selected from known sterilization methods
depending upon the types of carbonyl compound-trapping agent and
carrier used. The sterilization method includes, for example,
autoclaving, gamma-ray irradiation, gas sterilization, etc.
Carbonyl compound-trapping agent-immobilized carriers could
be contacted with blood in various ways. Examples are: the method
where collected patient blood is infused into a blood bag filled
with carbonyl compound-trapping agent-immobilized carriers, and
trapping the carbonyl compounds in patient blood; the method where
blood is circulated in a column filled with bead carriers or fiber
carriers, or the like, on which a carbonyl compound-trapping agent
has been immobilized, etc. Not only whole blood, but also seperated
blood plasma may be used for the treatment. The treated blood may
be returned to the patient or, if required, may be stored in a blood
bag, or the like. It is also possible to trap carbonyl compounds
that generate and accumulate in blood in blood bags during storage,
by including carriers on which carbonyl compound-trapping agents
are immobilized within the blood bags.
The contact between blood and carriers on which a carbonyl
compound-trapping agent of this invention has been imn.obilized can
be carried out during the blood purification step, including
hemodialysis, blood filtration, blood filtration dialysis, blood
adsorption, and blood plasma separation.
For example, both hemodialysis and trapping of carbonyl
compounds can be carried out simultaneously in nemodialysis
patients, by placing carriers on which a carbonyl compoand-trapping
agent has been immobilized in the hemodialysis circuit. In this
case, it is preferable to use the hemodialysis membrane as the
carrier on which a carbonyl compound-trapping agent has been
immobilized. Known types of dialysis membranes car_ be used as
carriers. Examples are, cellulose derivatives such as regenerated
cellulose, and cellulose triacetate; and polymeLhyl methacrylate,
CA 02373859 2002-11-06
11
polyolefin, polysulfone, polyacrylonitrile (PAN), polyamide,
polyimide, polyether nylon, silicon, and polyester copolymers, but
are not limited thereto. As shown in the Examples, when polysulfone
is used as the dialysis membrane, there was a decrease in the carbonyl
intermediate product (pentosidine) level. Thus, among the
above-mentioned dialysis membranes, it is particularly preferable
to use a polysulfone membrane as the carrier. Instead of using a
dialysis membrane as a carrier, a column filled witt carriers on
which a carbonyl compound-trapping agent has been immobilized may
indeed be placed in the hemodialysis circuit as described above.
Through contacting a patient's blood with carriers on which a
carbonyl compound-trapping agent has been immobilized, carbonyl
compounds are trapped from the blood, their damaging activity
towards the living body is eliminated, and they become nontoxic.
An anticoagulant may be used together to prevent blood-clotting in
an extracorporeal circulation. Such anticoagulants include, for
example, heparin, low-molecular-weight heparin, and Futhan
(Nafamostat mesilate) . These may be imn:obilized on carriers.
Ir. is predicted that. there maybe some cases where carbonyl
compounds in patient blood are not completely treated during
dialysis if the quantity of trapping agent used durinq the contact
with blood is too small. Since pre-determination of the quantity
of carbonyl compounds in the patient blood is particularly difficult,
it is effective to maintain the activity of as many trapping agents
as possible within a range that ensures the safety of the patient.
The dose of a trapping agent can be adjusted by altering the quantity
of trapping agent immobilized on the carriers, or the dose of
carriers on which the trapping agent has been immobilized.
In addition to the organic compounds represented by the above
Maillard reaction inhibitors, polymer compounds such as ion
exchange resin, or inorgariic compounds such as activated carbon,
silica gel, alumina, and calcium carbonate can also be used as
carbonyl compound-trapping agents of the present invention. These
compounds, which are known as filling agent:.s used for chromatography,
can trap carbonyl compounds due to their adsor_ption capability.
Such compounds themselves can functior,as carriers, and therefore,
for example, a filtrator installed within ari extracorporal blood
CA 02373859 2002-11-06
12
circulation circuit can be filled with them for use. Such a compound
can also be utilized as a "carbonyl compound-trapping agent"
comprised in the an agent for improving carbonyl stress state of
the present invention. In this case, such compounds themselves
function as carriers on which a carbonyl. compound-trapping agent
has been immobilized as described above. Alternatively, another
carbonyl compound-trapping agent can be further immobilized on
carriers themselves having the capability of trapping carbonyl
compounds.
An adsorbing-type blood-purification device =s known, in
which activated carbon is used. This adsorbing-type
blood-purification device is used for a supplemeritary method
associated with hemodialysis for the purpose of blood purification
in drug poisoning and hepatic coma, and the remova:L of various
intrinsic and extrinsic toxins and vasoactive substances increased
in the earlier phases of onset of acute renal failure associated
with multi-organ failure. However, it has been complete-l.y unknown
that such an adsorbing-type blood-purification device is effective
as a carbonyl compound-trapping agent.
Brief Description of the Drawings
Figure 1 shows the effect of changing the type of hemodialysis
membrane on blood plasma pentosidine levels (pmol/mg protein) in
3 patients. Each result is shown in a % value relative to the
corresponding initial value (41. 8 pmol/mg protein for patient 1(0) ,
22.1 pmol/mg protein for patient 2(11) or 28.5 pmol/mg protein
patient 3(LA)). Each value obtained is an average value of two
samples collected 2 weeks after the end of each dialysis period (in
the -2nd and Oth week of dialysis by AN69; in the 8th and l0rh week
after the switch to PS; in the 14 th and 16th weeks after the returning
to AN69).
Figure 2 shows the suppression effect on the pentosidine level
of blood piasma in dialysis patients by the incubation with beads
on which a carbonyl compound-trapping agent had been immobilized.
Figure 3 shows the carbonyl compound-trapping action by
activated carbon in a dicarbonyl compound solution.
Figure 4 shows the dicarbonyl compound-trapping action by
CA 02373859 2002-11-06
activated carbon in a peritoneal dialysate.
Figure 5 shows the activated carbon-mediated suppression
effect on pentosidine generation when blood plasma from a dialysis
patient was incubated at 37 C.
Figure 6 shows the removal of carbonyl compounds in blood
plasma of a renal failure patient by activated carbon, or sulfonyl
hydrazine-linked polystyrene beads. In this diagram, the ordinate
shows the carbonyl compound concentration.
Figure 7 shows the removal of carbonyl. compounds in blood
plasma of a renal failure patient by aminoguanidi_ne. In this
diagram, the ordinate shows the carbonyl compound ccncentration.
Figure 8 shows a method for preparing diaminoguanidine-linked
polyamide.
Figure 9 shows the removal of carbonyl compounds in a
dicarbonyl compound solution by diaminoguanidine-linked polyamide.
Best Mode for Carryirig out the Invention
The present invention is specifically illustrat:ed below with
reference to Examples, but it is not to be construed as being limited
thereto.
(Example 1] The influence of the type of hemodialysis membrane on
blood plasma pentosidine level
1. Patients
Belgian patients (n=29) and Japanese patients (n=97), 126
patients (69 males and 57 females) in total, who had been subjected
to hemodialysis 3 times a week, were tested. They were 61.2 13
(standard deviation) years old on average. Only two of them were
affected with mild type-II diabetes mellitus. Each patient used
the same type of hemodialysis membrane for at least 3 months (or,
2 or 3 patients used the same type of membrane for less than 3 months,
but ever since initiating hemodialysis) In 26 of 29 Belgian
patients, dialysis membranes were reused, but there was no reuse
in Japanese patients. Data of residual d_Luresis (ml/day) , surface
area of dialysis membrane, and duration of hemodialysis were
obtained from clinical records of each patient.
2. Types of membranes
CA 02373859 2002-11-06
14
The following hemodialysis membranes were used: high-flux (UF
index>10 ml/mmHg/h) AN69 (Hospal; France) (group of AN69);
high-flux polysulfone (Fresenius; Germany) (group of PS); high-flux
polysulfone (Asahi Medical; Japan) (group of APS); high-flux
polymethylmethacrylate (Toray; Japan) (group of PMMA); and low-flux
cellulosic (Asahi Medical; Japan) (group of cellulose).
3. Blood plasma samples
Blood plasma samples were collected from all the 126 patients
prior to the first hemodialysis, and then from 66 patients weekly
after dialysis.
All the samples were immediately subjected to centrifugal
separation. The blood plasma samples frozen at -20 C were tested
as follows:
4. Quantification of total pentosidine and free pentosidine
For quantification of total pentosidine, a sampl.e (50 ~Ll) was
lyophilized, dissolved in 100 pl of 6N HC1, encapsulated with
nitrogen gas and then incubated at 110 C for 16 hours, neutralized
with 100 l of 5N NaOH and 200 pl of 0.5 M phosphate buffer (pH 7.4),
subsequently filtered through a filter with a pore size of 0.5 ~un,
and diluted 20 times with PBS. For quantification of the free
pentosidine, the sample (50 l) was mixed with an equal amount of
10% TCA, and then centrifuged at 5000 X g for 10 minutes. The
supernatant was filtered through a filter with a pore size of 0.5
m and diluted 4 times with distilled water.
Pentosidine in each of these samples was analyzed by reverse
phase HPLC using a C18 reverse phase column (Waters, Tokyo, Japan)
(Miyata, T. et al., J. Am. Soc. Nephrol., 7: 1198-1206, 1996). The
effluent was monitored with a fluorescence detector (RF-10A;
Shimadzu) at an excitation/detection wavelength =335/385nm. A
standard curve was prepared by using synthetic pentosidine.
The level of protein-bound pentosidine (pentosidine/protein)
(pmol/mg protein) was calculated by jtotal pentosidine in blood
plasma (pmol/ml) - free pentosidine (pmol/ml)]/[blood plasma
protein concentration (mg/ml)].
5. Statistical analysis between groups of patients
The respective values, including quantification of the
pentosidine level, are indicated as mean standard deviation or
CA 02373859 2002-11-06
percentage ($). The data of residual diuresis was log-transformed.
Through one-way analysis of variance (one-way ANOVA) (with F-test) ,
individual data and the pentosidine level were compared between
groups of hemodialysis patients using different dialysis membranes.
5 Furthermore, the groups of dialysis membranes were compared and
analyzed by using Bonferroni t-test. Through chi 2 test, the degree
of residual diuresis was compared between the various groups.
The result of cross-sectional analysis among the five groups
of patients is shown in Table 1. There were no significant
10 age-related differences among the groups. The blood plasma protein
level was higher in the AN69 and cellulosic groups. In APS group,
the area of the dialysis membrane was larger, and both the period
of hemodialysis prior to the study and duration of a single dialysis
were longer. On the other hand, residual diuresis was higher in
the PS group.
CA 02373859 2002-11-06
16
Table 1
jO00OII > Q OOOOO t >~
QD- vvvvZ a
E
cp ~1 O cV
j, OO~-et M CO 0O rn
Cqr l-H MON N CD
-p v q T
CO
+=1 L W
N cv c~
4~N]~M >+,
1[) cD O C G ^ O ~
~!=1 .}1 i'1 +1 +I ; ~ N ~~
c N cD et - et ta +~
0= cD~~Co=jOM ~ Lrn
m c4
4"i d C9 d' m -0
'0v
1A (6 0o0C cV) p
a>a~
z -H +1 +1 +1 +1 +1 v (D EU
~ Q C~ GO OO C~ M N M a N ~ E
(D 1~ tC C7 T~ tn O
C~
0
-1 ==+ U a~
r-L M4001'- le ~M O0
W,-ca0000 ~c=)u') + O
d a +1 'F1 +1 =F1 +1 =#.1 c .3 O c4-
co CQ'It MtO~N ~
T teN
Q p~
r-L LAtoe~fN O-
d
O
L V Q ttiOLO i C
N LC! M
(/)CAr, ~?ONO 000 0 v~i aEiU
+-,
0 N ~f ^ +1 rnI ~ /o tM oo ~ E
eto - o a na=-
U'j r": ai u-i~ Q -~ o o~
C L n ~ 0 o 0 oR c
o E
= a ~. g o~ Q an a`n a`o a~o cu =-
tw n. dLA 0 ~~ 0) a) G) -p = U N
M dA 00 W N CO p y ~
~ _a - N S E^ C Qc 40 ~ G .t 0 E>' a
~ cn ~ tA f4 m i~O 7 O L t1 cp
~ - '-=- -0 cn~za~-=-=
- a~_ C T T E Q. a a a a V V tv V~i~~ C
R3 = E C9 ~p. ~~ N y tA lA fN UJ N tA tA y- >,
~ =-' N =- - y ~ > > > > > > > > > 0-0 y..,
Q i-~ ~ =a v = ~. _
d 9 O E~ `n O O u~ ~Cl +-- 1c~ ~ O ua a' ~ o
.1.~ w ~c m E~~ ~ 000 00 O O 00 ~ X ~
Rco~ ~=- E - O O G O C O O O L~ o
~ .- E E4. o~ v V V V~/ V~/ V~/ 11 4''
(/) L o h N o m- V C. a a Cx a a a Q. a fb !n =
m m
- - r_ ~ ~ +L+ ii u n n u n ;i ir ii ~, -
o n o .o (, tto t41 o
~ m 4 O O Q) 0p (D
iF ~ -Il= O O a ~ ~ = ~ ~
CA 02373859 2002-11-06
1!
Before dialysis, the levels of protein-bound pentosidine and -
of free pentosidine in blood plasma were similar among the AN69,
PMMA, and cellulosic groups, but were significantly lower in the
PS and APS groups. There was no significant difference between the
PS and APS groups (Table 2).
CA 02373859 2002-11-06
18
Table 2
a~
z >o o
Q ~ v v
U
ocla0
1+1
U C-)
UO
Q r
cv)
N ~ N
nw a ~C N +1
CD M
N
co
C~
UM
I-E EQ~'c+1 +l
1[)
N r,.,
F-~ Gf
ao N
+l+1
y cU')
(D co M
aii+1~
_ a ~C!
C`N')
Co.
0
(D
~
O
co
T a
- bp I
cc o
bD
0 E U)
a Q
a- ~ 0
ca
4-J a
o ~ cn
aII a-
aD '- ~
C ~/J 7
0
o
o
Q
o a
> ~
CA 02373859 2002-11-06
19
Univariate analysis of a variety of factors that may influence
predialysis blood plasma pentosidine, indicated that residual
diuresis significantly affected protein-bound and free
pentosidine: the higher the residual diuresis, the lower the
pentosidine level. No correlation was found betweeri pentosidine
level and blood plasma protein level, albumin level, age, or dialysis
history (Table 3). Relating to polysulfone (PS and APS groups)
groups, the predialysis pentosidine level in Belgian patients or
Japanese patients subjected to dialysis with polysulfone membranes
from Fresenius or Asahi Medical co. were similar to each other (Table
4).
Table 3
Univariate analysis of the relationship between pentosidine level and
notentiallv exolanatorv continuous variables: r values
sis Total protein Alubumin Age Duration
pentos i d i ne prote i n -0.28 -0.08 0 0.14 0.03
free pentos i d i ne -0.36 0.01 -0.12 0.15 0.02
# = p<0.01
p<0.001
Table 4
Pentosidine levels and residual diuresis in polysulfone groups,
according to polysulfone brand and/or country of patients
Fresenius Fresenius Asahi P va I ue
Belgium Japan Japan
pentos i I ne prote i n 14.6:t 6.2 15.3 6.3 16.2- -~4.8 NS
(pmol/mg protein)
free pentosidine(pmol/ml) 37.3 19.6 45.4t25.9 32.4 11.3 NS
r es i dua l d i ur es i s(m l/day) 938(23) 49(14) 47(10) 0.004
As described above, it was revealeci that pentosidine levels
were lower in dialysis patients using polysulfone dialysis
membranes than those in dialysis patierlts using other dialysis
membranes. Decreases in pentosidine levels were seen in patients
dialyzed with a polysulfone membrane, independent of the patients'
country or the manufacturer of the dialysis membranes. Furthermore,
although patients subjected to dialysis with polysulfone dialysis
CA 02373859 2002-11-06
membrane from Ashahi Medical were substantially anuric, pentosidine -
levels were similarly lower. In the group using polysulfone from
Fresenius, there was no alteration in statistical significance in
the difference of pentosidine level, even when patients with urinary
5 volumes greater than 300 ml/min were excluded.
Because AN69 is also high-flux type and pentosidine levels
before dialysis in dialysis with high-flux AN69 and low-flux
cellulosic showed similar results, the difference in. pentosidine
level is estimated to be independent of the removing capacity of
10 dialysis membrane.
The relationship between protein-corrected pentosidine level
or free pentosidine level and residual diuresis was analyzed by
linear regression analysis. The effect of each explanacory
variable on dependent variable (protein-corrected pentosidine
15 level and free pentosidine level) was tested by variable selection
- multiple regression analysis (Forward stepwise multiple
regression analysis) . All the analyses were carried out by using
BMDP statistics software (BMDP is the trade mark of New System
Professional Edition: Statistical Solutions Inc., University of
20 California Press, Berkeley, 1995). A P value less than 0.05 was
considered significant.
The analysis result showed that dialysis membrane type and
residual diuresis were the two sole independent determinants of
protein-bound and free pentosidine levels (Table 5). Considering
the fact that none of the interactions were significant, the
influence of residual diuresis on pentosidine level was not affected
by dialysis membrane type.
CA 02373859 2002-11-06
'L 1
Table 5
The variable selection-multiple regression analysis of determinants of
pentosidine levels
(Forward stepwise multiple regression analysis)
pentosidine/protein free pentosidine
Increase in R P value Increase in R P value
membrane type 0.53 <0.001 0.59 <0.001
lo&. diuresis -0.21 <0.001 -0.36 <0.001
total prote i n -0.17 NS 0.05 NS
a l bum i n -0.05 NS -0.1 NS
age 0.12 NS 0.16 NS
per i od of hemod i a l ys i s -0.01 NS -0.08 NS
6. The effect of dialysis membrane on pentosidine levels before and
after hemodialysis
To further analyse the mechanism underlying dialysis membrane
effect on predial.ysis pentosidine levels, pentosidine levels before
and after dialysis were determined for four groups of patients with
high-flux polysulfone (Fresenius), AN69, PMMA, or low-flux
cellulosic dialysis membranes (Table 6).
Table 6
Influence of a single hemodialysis session on pentosidine level
PS AN69 PMMA ce l l u l os i c
n=14 n=15 n=9 n=28
pentosidine/protein(pmol/mg protein)
Pre 14.6t6.2 25.4t8.4 24.3t8.5 21.8 6.4
Post 13.8t6.6 23.4t5.6 22.8t8.3 22.1 t5.8
free pentosidine(pmol/ml)
Pre 37.3t19.6 76.4 28.5 70.3t26 53.5t18.5
Post 10.9t6.6 17.5t4.9 21.74-7 14.7t6.9
(reduction ratio) (%) (71 t 11) (76 t 7) (67 t 9) (73 t 6)
As predicted by the above experiment, the level of
protein-bound pentosidine was almost unaltered and also was
independent of the dialysis membrane type. Although only the level
of free pentosidine markedly decreased, the percentage, which was
between 76%(AN69) and 67%(PMMA) was sintilar in all the groups.
There was no significant difference among the groups. Thus, it was
revealed that the lower predialysis pentosidine levels observed in
dialysis patients using polysulfone fnembranes could not be
CA 02373859 2002-11-06
22
accounted for by differences in the dialysis capacity of the
membranes.
The present inventors previously showed that hemodialysis
itself did not affect the total pentosidine or protein-bound
pentosidine levels (Miyata, T. et al., Kidney Int., 51: 880-887,
1997). This finding agrees with the fact that 95% of pentosidine
bind with albumin that cannot be eliminated through dialysis (Miyata,
T. et al., J. Am. Soc. Nephrol. , 7: 1198-1206, 1996) . This finding
is supported by the result obtained in the above Example with the
four different types of dialysis membranes. On the contrary, the
amount of free pentosidine decreased by hemodialysis, and a similar
phenomenon was observed with every dialysis membrane. This result
is predictable by the molecular weight of free pentosidine (379 Da) .
The fact that pentosidine levels before and after hemodialysis were
similar for all the dialysis membranes indicates that not only
passive transport, but also absorption of pentosidine occurs during
dialysis with polysulfone or other dialysis membranes. The level
of absorption of radio-labeled free pentosidine with cellulosic
membrane or polysulfone membrane in vitro is very small, and in
reality, there was no difference.
Thus, the decreased predialysis pentosidine level cannot be
explained by the fact that the polysulfone membrane enhances removal
of pentosidine . There may be another possibility that the dialysis
with polysulfone membrane relates to the suppressi.on of pentosidine
production.
As pointed out previously, pentosidine level reflects the
concentration of carbonyl intermediates derived from carbohydrates.
The polysulfone membrane has the specific effect of removing these
carbonyl compounds, and thus, it may be having an effect on
pentosidine production. Alternatively, there may be also the
possibility that the polysulfone membrane reduces oxidative stress
assumed to be associated with uraemia (Miyata, T. et al., Kidney
Int., 54; 1290-1295, 1998; Miyata, T. et al., Kidney Int., 51:
1170-1181, 1997; Loughrey, CM. et al. , Q. J. Med. , 87: 679-683, 1994;
Ueda, Y. et al. , Biochem. Biophys. Res. Commun. , 245: 785-790, 1998;
Kumano, K. et al., Adv. Perit. Dia1., 1992; 8: 127-130; W.itko-Sarsat,
V. et al., Kidney Int., 49: 1304-1313, 1996). There is also the
CA 02373859 2002-11-06
possibility that the decrease in oxidative stress suppreses the
production of carbonyl compounds, and as a result, the generation
of pentosidi.ne is decreased (Miyata, T. et al., Kidney Int., 51:
1170-1181, 1997).
7. The effect of switching the dialysis membrane on the pentosidine
level
To verify the specific pentosidine-lowering effect of
polysulfone, a longitudinal analysis was conducted irithree anuria
patients subjected to long-term (>5 years) AN69 dialysis. The
patients were switched to a polysulfone (Fresenius) dialysis
membrane of similar surface area for 10 weeks, and subsequently,
the membrane was returned to AN69. Predialysis samples were
collected every 2 weeks before the switch to PS (2 samples) , during
PS dialysis (5 samples), and 14-16 weeks after the return to AN69
(2 samples).
It was found that protein-bound pentosidine level of each
patient gradually decreased after switching to PS dialysis, and
subsequently, due to the resumption of AN69 dialys:.s, the level
returned to that when using AN69 prior to the switch to PS (Figure
1).
The decrease in pentosidine level observed in the longitudinal
study in patients, which was carried out by switching AN69 to PS
dialysis, is only one third of the difference (10.4 compared to 3.6
pmol/mg protein) between the PS and AN69 groups observed in the
cross-sectional study. This discrepancy may be due to the fact that
the observation after the transfer to PS dialysis lasted only 10
weeks. If polysulfone reduces the rate of pentosidine generation,
it will be possible to explain the fact that protein-bound
pentosidine decreased so slowly. Under such circumstances, the
decrease in protein-bound pentosidine level may result from only
protein metabolism. A similar observation was made after
successful kidney transplantations. In such cases, the decrease
in protein-bound pentosidine was considerably slower than the
decrease in blood plasma (32-microglobulin, suggesting that the
decrease occurs very slowly, and the decomposition of protein-bound
pentosidine is very slow (Miyata, T . er_ al ., Kidney Int., 51: 880-887,
1997; Hricik, DE. et al., Clin. Transplantation, 10: 568-573, 1996).
CA 02373859 2002-11-06
24
[Example 2] The removal of blood carbonyl compounds by carriers on
which a carbonyl compound-trapping agent has been immobilized
A cross-linked polystyrene resin boundto a sulfonyl hydrazine
group (PS-TsNHNH2, ARGONAUT TECHNOLOGIES) was used as a carbonyl
compound-trapping bead to study its effect in removing blood
carbonyl compounds. Blood plasma from a dialysis patient and those
supplemented with carbonyl compound-trapping beads were incubated
at 37 C to test the pentosidine generation-suppressing effect. 100
Rl of dimethylsulfoxide was added to the tube containing carbonyl
compound-trapping beads to swell the beads, and then
filter-sterilized blood plasma from a predialysis dialysis patient
was added thereto. The mixture was incubated at 37 C for one week.
After incubation, the beads were removed with a centrifugal filter
having a pore size of 0.22 m(Millipore, UFC30GV00). Then, 50 l
of 10% trichloroacetic acid was added to 50 l of the bead-free
solution, and the mixture was centrifuged to precipitate proteins.
The resulting protein pellet was washed with 300 ~tl of 5%
trichloroacetic acid and then dried. Subsequently, 100 ~ti of 6N
Hci was added to the pellet and heated at 110 C for 16 hours, and
then, pentosidine was quantified by HPLC (Miyata, T. et al., 1996,
J. Am. Soc. Nephrol., 7: 1198-1206, Miyata, T. et al.., 3.996, Proc.
Natl. Acad. Sci. USA, 93: 2353-2358).
The amount of pentosidine generated during incubation at 37 C
is shown in Figure 2. It was found that the addition of carbonyl
compound-trapping beads suppressed the generation of oentosidine.
In addition, the suppression of pentosidine generation depended on
the amount of carbonyl compound-trapping beads added.
These results showed that blood carbonyl compounds could be
removed by carriers on which the carbonyl compound-trapping agent
had been immobilized. Further, it was revealed that polysulfone
membrane was a particularly suitable hemodialysis membrane for
improving carbonyl stress state.
[Example 3] The removal of carbonyl compounds from a dicarbonyl
compound solution by activated carbon
900 l of a dicarbonyl solution, in which each of glyoxal,
CA 02373859 2002-11-06
Zb
methylglyoxal, and 3-deoxyglucosone had been dissolved (100 M each)
in PBS (-) , was added to a tube containing 25 mg or 50 mg of activated
carbon (Wako Pure Chemical Industries) and the mixture was stirred
with a rotator at room temperature for 19 hours. Then, the solution
was filtered through a centrifugal filtration tube with a pore size
of 0.22 m (Millipore; UFC30GV00) and the concentrations of glyoxal,
methylglyoxal, and 3-deoxyglucosone in the filtrate were measured
by high-performance liquid chromatography.
When 900 l of the dicarbonyl solution was added to 25 mg of
activated carbon, 71% of glyoxal, 96% of inethylglyoxal, and 97% of
3-deoxyglucosone were trapped. When 50 mg of activated carbon was
used, 85% of glyoxal, 98% of inethyiglyoxal, and 98% of
3-deoxyglucosone were trapped (Figure 3i.
[Example 4] The removal of dicarbonyl compounds from a peritoneal
dialysate by activated carbon
Since typically, a peritoneal dialysate contains a high
concentration of glucose, glucose-derived carbonyl compounds are
produced duringsterilization or storage. These carbonylcompounds
are transferred into the living body during peritoneal dialysis,
which is one factor causing carbonyl stress state. Thus, the effect
of the carbonyl compound-trapping agent of the present invention
in removing carbonyl compounds from a peritoneal dialysis liquid
was evaluated.
900 l of a peritoneal dialysate (Baxter Ltd. ; Dianeal PD-4,
1.5) was added to a tube containing 25 mg or 50 mg of activated carbon
and the mixture was stirred with a rotator at room temperature for
19 hours. Then, the solution was filtered through a centrifugal
filtration tube with a pore size of 0.22 m (Millipore; UFC30GV00) ,
and the concentrations of glyoxal, methylglyoxal, and
3-deoxyglucosone in the filtrate were measured by high-performance
liquid chromatography.
When 900 l of peritoneal diaLysate was added to 25 mg of
activated carbon, 56% of glyoxal, 71% of inethylglyoxal, and 62% of
3-deoxyglucosone was trapped. When 900 l of peritoneal dialysate
was added to 50 mg of activated carbon, 64% of glyoxal, 78% of
methylglyoxal, and 77% of 3-deoxyglucosone were trapped (Figure 4)
CA 02373859 2002-11-06
26
[Example 5] The pentosidine generation-suppressing effect of
activated carbon when blood plasma from a dialysis patient was
incubated at 37 C
250 l of filter-sterilized blood plasma from a predialysis
dialysis patient was added to a tube containing 12 mg of activated
carbon suspended in PBS(-), and the mixture was incubated at 37 C
for one week. After incubation, 50 l of 12N HCI was added to 50
l of supernatant obtained by centrifugation, and the mixture was
heated at 110 C for 16 hours for hydrolysi.s. Then, peritosidine was
quantified by high-performance liquid chromatography (Miyata, T.
et al., 1996, J. Am. Soc. Nephrol., 7:1198-1206, Miyata, T. et al.,
1996, Proc. Natl. Acad. Sci. USA., 93:2353-2358).
The amount of pentosidine generated by the incubation at 37 C
is shown in Figure 5. When compared with the control, 51% of
pentosidine generation was suppressed by the addition of activated
carbon. This suggested that carbonyl compounds that are precursors
of pentosidine were adsorbed by activated carbon.
[Example 6] The removal of carbonyl compounds from blood plasma by
activated carbon
500 l of blood plasma from a renal failure patient was added
to a tube containing 20 mg or 50 mg of activated carbon (Wako Pure
Chemical Industries) , and then the mixture was stirred with a rotator
at room temperature f or 12 hours. After the separation of activated
carbon by centrifugation, the concentrations of glyoxal and
methylglyoxal in blood plasma were measured by high-performance
liquid chromatography.
The concentrations of glyoxal and methylglyoxal in blood
plasma were measured as follows. First, 300 l of 0.67M perchloric
acid was added to 200 l of blood plasma, and then, the mixture was
stirred and centrifuged to separate the supernatant. 20 g1 of 1%
o-phenylenediamine and 50 ~L1 of 10 M 2,3-butanedione (internal
standard) were added to 150 l of the supernatant. The mixture was
stirred and incubated at 25 C for 1 hour. According to the method
described by Ohmori et al.(Ohmori, S. et al., J. Chromatogr. , 414:
149-155, 1987), quinoxaline derivatives generated via the reaction
CA 02373859 2002-11-06
between glyoxal or methylglyoxal and o-phenylenediamine were
separated for the quantification by HPLC with a reversed-phase
column.
The result is shown in Figure 6. When 20 mg of activated carbon
was added to blood plasma, 58% of glyoxal and 65% of inethylglyoxal
were trapped. When 50 mg of activated carbon was added, 75% of
glyoxal and 80% of methylglyoxal was trapped.
[Example 7] The removal of carbonyl compounds from blood plasma by
sulfonyl hydrazine-linked polystyrene beads (Ps-TsNHNH2)
500 l of blood plasma from a renal failure pati.ent was added
to a tube containing 10 mg or 20 mg of sulfonyl hydrazine-linked
polystyrene beads and then the mixture was stirred with a rotator
at room temperature for 12 hours. After the separation of sulfonyl
hydrazine-linked polystyrene beads by centrifugation, the
concentrations of glyoxal and methylglyoxal in blood plasma were
measured by high-performance liquid chromatography according to the
same method as in Example 6. The result is shown in Figure 6. When
10 mg of sulfonyl hydrazine-linked polystyrene beads were added to
blood plasma, 45% of glyoxal and 39% of methylglyoxal were trapped.
When 20 mg of sulfonyl hydrazine-linked polystyrene beads were added,
75% of both glyoxal and methylglyoxal were trapped.
[Example 8] The removal of carbonyl compounds from blood plasma by
aminoguanidine
50 Vl of a solution in which aminoguanidine (50 mM, or 100
mM) was dissolved in 0.1M sodium phospnate buffer (pH 7.4) was mixed
with 450 l of blood plasma from a renal failure patient, and the
resulting mixture was left at room temperature for 12 hours. After
12 hours, the concentrations of glyoxal and methylglyoxal in blood
plasma were measured by high-performance liquid chromatography
according to the same method as in Example 6.
The result is shown in Figure 7. When aminoguanidine
concentration in blood plasma was 5 mM, 50% of glyoxal and 46% of
methylglyoxal were trapped. When aminoguanidine concentration was
10 mM, 58% of glyoxal and 70% of inethylglyoxal were trapped.
CA 02373859 2002-11-06
28
[Example 9] The removal of carbonyl compounds by carriers on which -
a carbonyl compound-trapping agent has been immobilized
The action of removing carbonyl compounds by carriers, on
which a carbonyl compound-trapping agent has been immobilized, was
evaluated by using diaminoguanidine-linked polyamide.
Diaminoguanidine-linked polyamide was prepared by reacting
polyamide with epichiorohydrin and adding an aqueous solution of
diaminoguanidine (pH 12) thereto, followed by incubation at 80 C
for about 1 hour (Figure 8) . After the reaction was completed, the
resulting diaminoguanidine-linked polyamide was washed with water
and then dried for use in the subsequent experiments.
lml of a dicarbonyl compound solution (glyoxal, methylglyoxal,
3-deoxyglucosone; 1 M each in PBS (pH 7.4)) was added to a tube
containing 30 mg of diaminoguanidine-linked polyamide. The mixture
was stirred with a rotator at room temperature (25 C) for 5 hours,
and 100 Itl of those were centrifuged. The res.idual glyoxal,
methylglyoxal, and 3-deoxyglucosone in the supernatant were
converted to derivatives thereof, and were determined by
high-performance liquid chromatography. The result is shown in
Figure 9. 30% of glyoxal, 56% of inethylglyoxal, and 11% of
3-deoxyglucosone were trapped. When diaminoguanidine-free
polyamide was used as a negative control under the same conditions,
the above carbonyl compound-trapping action was not detectable.
The results described above verified that the carbonyl
compounds could be removed effectively from the liquid by carriers
on which the carbonyl compound-trapping agent has been immobilized.
Industrial Applicability
The present invention enables effective removal of blood
carbonyl compounds. The agent of the present invention for
improving carbonyl stress state can be used readily by immobilizing
it on a dialysis membrane for hemodialysis, or alternatively
immobilizing it on other carriers and placing it within the blood
circuit. Thus, the present invention makes it possible to ease
damages caused by carbonyl compounds (i.e. carbonyl stress) from
which renal failure patients have long suffered.
